News
Citigroup Maintains Buy on CRISPR Therapeutics, Raises Price Target to $89
18 Apr 24
News, Price Target, Analyst Ratings
Needham Reiterates Buy on CRISPR Therapeutics, Maintains $90 Price Target
11 Apr 24
News, Price Target, Reiteration, Analyst Ratings
If You Invested $1000 In This Stock 5 Years Ago, You Would Have $2,000 Today
19 Mar 24
News, Trading Ideas
Cathie Wood's Ark Invest Keeps Dumping Coinbase Shares Amid Bitcoin, Crypto Buzz
12 Mar 24
Cryptocurrency, Equities, News, Markets, ETFs
Median Drug Prices For Rare Diseases Hit $300K In 2023, Report Highlights Lack of Clear Rationale Behind Escalating Drug Prices
26 Feb 24
Biotech, Large Cap, News, Health Care, Markets, General
Morgan Stanley Maintains Underweight on CRISPR Therapeutics, Raises Price Target to $48
26 Feb 24
News, Price Target, Analyst Ratings
If You Invested $1000 In This Stock 5 Years Ago, You Would Have $2,100 Today
23 Feb 24
News, Trading Ideas
Smart Money Is Betting Big In CRSP Options
22 Feb 24
Options, Markets
RBC Capital Maintains Sector Perform on CRISPR Therapeutics, Raises Price Target to $66
22 Feb 24
News, Price Target, Analyst Ratings
Analog Devices To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Thursday
22 Feb 24
News, Price Target, Small Cap, Pre-Market Outlook, Markets, Analyst Ratings, Trading Ideas
Chardan Capital Maintains Buy on CRISPR Therapeutics, Raises Price Target to $112
22 Feb 24
News, Price Target, Analyst Ratings
Needham Maintains Buy on CRISPR Therapeutics, Raises Price Target to $90
21 Feb 24
News, Price Target, Analyst Ratings
What's Going On With Crispr Therapeutics Stock?
15 Feb 24
News, Analyst Ratings, Movers
Reliance Steel & Aluminum Posts Upbeat Earnings, Joins JFrog, AppLovin, Shake Shack And Other Big Stocks Moving Higher On Thursday
15 Feb 24
News, Penny Stocks, Small Cap, Intraday Update, Markets, Movers, Trading Ideas
Wolfe Research Initiates Coverage On CRISPR Therapeutics with Peer Perform Rating
15 Feb 24
News, Initiation, Analyst Ratings
Check Out What Whales Are Doing With CRSP
14 Feb 24
Options, Markets
CRISPR Therapeutics Announces $280M Registered Direct Offering At $71.50/Share
13 Feb 24
News, Offerings
European Commission Approves First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY (Exagamglogene Autotemcel), for the Treatment of Sickle Cell Disease (SCD) and Transfusion-Dependent Beta Thalassemia (TDT)
13 Feb 24
Government, News, Regulations
$1000 Invested In This Stock 5 Years Ago Would Be Worth $2,300 Today
9 Feb 24
News, Trading Ideas
Jim Cramer Says It's 'Still Not Too Late' To Buy This Energy Stock
31 Jan 24
Long Ideas, News, Top Stories, Markets, Media, Trading Ideas
Press releases
CRISPR Therapeutics to Present at the Annual Needham Virtual Healthcare Conference
3 Apr 24
News, Press Releases
CRISPR Therapeutics to Present at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting
1 Apr 24
News, Press Releases
CRISPR Therapeutics Proposes New Appointment to the Board of Directors
13 Mar 24
News, Management, Press Releases
CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
21 Feb 24
Earnings, Press Releases
CRISPR Therapeutics Announces $280 Million Registered Direct Offering
13 Feb 24
Press Releases
European Commission Approves First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), for the Treatment of Sickle Cell Disease (SCD) and Transfusion-Dependent Beta Thalassemia (TDT)
13 Feb 24
Health Care, Press Releases